Revolution Medicines’ pan-RAS inhibitor daraxonrasib posted phase 3 results that nearly doubled overall survival in metastatic pancreatic ductal adenocarcinoma versus investigator-selected chemotherapy. Presented at ASCO 2026 and published alongside the conference reporting in the New England Journal of Medicine, the RASolute 302 trial included 500 previously treated patients. Across the overall population, median survival was 13.2 months with daraxonrasib compared with 6.7 months for chemotherapy. Disease progression was also delayed, with median time to worsening and progression-free dynamics favoring daraxonrasib in both the full cohort and the subgroup with the most common RAS mutations. Oncologists highlighted the magnitude of the survival gap after years of limited progress in pancreatic cancer drug development.